In spite of these limitations, our study is the first in humans to identify the important mediating role of FGF21 in the relationship between thyroid cancer aggressiveness and metabolic dysregulation, and suggested that increased serum levels of FGF21 in patients with thyroid cancer may be a useful biomarker for tumor progression. Here, FGF21 is linked to neoplasm.